Check-Cap (NASDAQ:CHEK) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research note published on Wednesday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

NASDAQ:CHEK opened at $0.92 on Wednesday. The firm has a market cap of $5.38 million, a price-to-earnings ratio of -0.31 and a beta of 0.16. The firm’s fifty day moving average price is $1.08 and its 200 day moving average price is $1.37. Check-Cap has a 1-year low of $0.56 and a 1-year high of $3.45.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.